Decision Advisory for Biotech Leaders
As an owner-managed Swiss advisory boutique, we support biotech and pharma companies in valuation-driven strategic decisions, partnering and transactions.
Our Expertise
Entrepreneurial Valuation
We use valuation as a decision-making toolkit to understand value development, identify key value drivers and assess strategic options, including:
-
Multi-scenario valuations of companies and assets
-
Value creation pathways along key development and financing milestones
-
Key value driver analysis and sensitivity simulations
-
Management view compared with investor and strategic buyer perspectives
-
Valuation gap analysis to strengthen and defend company value
Partnering and M&A Advisory
We support biotech and pharma companies in preparing and executing partnering and transaction processes, including:
-
Buy-side and sell-side M&A advisory and transaction support
-
Identification of target companies, licensing partners and pipeline assets
-
In- and out-licensing strategy and execution
-
Opportunity assessment and due diligence support
-
Deal and milestone structuring and negotiation guidance
Our Tools
Investor & Deal Cockpit
Specialized modules for financing and transaction analysis, integrated into the Valuation Cockpit or used as standalone analyses.
Our Team
Partner
Mischa Csendes
With over 20 years of experience as an entrepreneur, in business development at Big Pharma, and in various commercial positions across listed companies and start-ups, Mischa brings a unique combination of strategic thinking and hands-on industry knowledge. Before founding Ocean21 in 2024, he spent five years in the M&A team at Vifor Pharma, where he was part of the deal teams for several acquisitions and licensing transactions.
.jpg)
Partner
Ben Kohler
With more than 15 years of CFO, controlling, and consulting experience, Ben combines strong analytical thinking with deep financial modelling expertise. Before joining Ocean21, Ben spent five years at a leading European real estate valuation company and, before that, served as CFO at a Swiss technology start-up.
Senior Advisor
Dr. Ivan Csendes
With over 35 years of experience in pharmaceutical business development, Ivan brings deep expertise in licensing, strategic partnering, and deal-making. He held senior roles at Novartis and later advised biotech and pharma companies across Europe. Ivan is Co-founder and past president of the Swiss Pharma Licensing Group and past president of the European Pharma Licensing Council. He has also served on multiple biotech boards, including as chairman.
Our Network
We work with a network of senior industry experts and advisors to complement our core team where needed. This allows us to bring in specialized expertise, for example in pricing, market access or due diligence, while maintaining a focused and senior advisory approach.
Our Philosophy
Ocean symbolizes the depth, constant movement, and global interconnectivity of the biotech and pharma industries. 21 represents the 21st century - an era of rapid medical innovation and technological progress.Together, Ocean21 is our commitment to navigating life science decision-makers through valuation-driven decisions, partnering and transactions with entrepreneurial thinking and analytical precision.
We support biotech leaders and investors in making better value-driven decisions and navigating complex transactions.
Ocean21 GmbH
Nidelbadstrasse 65, 8038 Zürich, Switzerland | contact@ocean21.ch
CHE-134.891.823
Designed by Muriel Imfeld